Effectiveness of disease management programs in depression: A systematic review

被引:169
作者
Badamgarav, E
Weingarten, SR
Henning, JM
Knight, K
Hasselblad, V
Gano, A
Ofman, JJ
机构
[1] Cerner Co, Zynx Hlth, Beverly Hills, CA 90212 USA
[2] TAP Pharmaceut Prod Inc, Lake Forest, IL USA
[3] Duke Univ, Duke Clin Res Inst, Durham, NC USA
[4] Cedars Sinai Hlth Syst, Dept Med, Los Angeles, CA USA
关键词
D O I
10.1176/appi.ajp.160.12.2080
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective: The authors systematically evaluated the published evidence to assess the effectiveness of disease management programs in depression. Method: English-language articles on depression were identified through a MEDLINE search for the period from January 1987 to June 2001. Two reviewers evaluated 16,952 published titles, identified 24 depression disease management programs that met explicit inclusion criteria, and extracted data on study characteristics, interventions used, and outcome measures. Pooled effect sizes were calculated by using a random-effects model. Results: Pooled results for disease management program effects on symptoms of depression showed statistically significant improvements (effect size=0.33, N=24). Programs also had statistically significant effects on patients' satisfaction with treatment (effect size=0.51, N=6), patients' compliance with the recommended treatment regimen (effect size=0.36, N=7), and adequacy of prescribed treatment (effect size=0.44, N=11). One program with an explicit screening component showed significant improvement in the rate of detection of depression by primary care physicians (effect size=0.66); two other programs lacking a screening component showed small nonsignificant improvements in the detection rate (effect size=0.18). Disease management programs increased health care utilization (effect size=-0.10, N=8), treatment costs (effect size=-1.03, N=3), and hospitalization (effect size= 0.20, N=2). Conclusions: Disease management appears to improve the detection and care of patients with depression. Further research is needed to assess the cost-effectiveness of disease management in depression, and consideration should be given to more widespread implementation of these programs.
引用
收藏
页码:2080 / 2090
页数:11
相关论文
共 59 条
[1]   Comorbidity of mood disorders: A longitudinal prospective study [J].
Angst, J .
BRITISH JOURNAL OF PSYCHIATRY, 1996, 168 :31-37
[2]  
Ballenger JC, 1999, J CLIN PSYCHIAT, V60, P54
[3]  
Banerjee S, 1996, BRIT MED J, V313, P1058
[4]  
Brown J B, 2000, Jt Comm J Qual Improv, V26, P39
[5]   IMPROVING TREATMENT OF LATE-LIFE DEPRESSION IN PRIMARY-CARE - A RANDOMIZED CLINICAL-TRIAL [J].
CALLAHAN, CM ;
HENDRIE, HC ;
DITTUS, RS ;
BRATER, DC ;
HUI, SL ;
TIERNEY, WM .
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 1994, 42 (08) :839-846
[6]  
Cohen J., 1998, Statistical Power Analysis for the Behavioral Sciences, V2nd
[7]   A critical review of selected pharmacoeconomic analyses of antidepressant therapy [J].
Conner, TM ;
Crismon, ML ;
Still, DJ .
ANNALS OF PHARMACOTHERAPY, 1999, 33 (03) :364-372
[8]   Effects of a multicomponent intervention on functional outcomes and process of care in hospitalized older patients: A randomized controlled trial of Acute Care for Elders (ACE) in a community hospital [J].
Counsell, SR ;
Holder, CM ;
Liebenauer, LL ;
Palmer, RM ;
Fortinsky, RH ;
Kresevic, DM ;
Quinn, LM ;
Allen, KR ;
Covinsky, KE ;
Landefeld, CS .
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2000, 48 (12) :1572-1581
[9]   METAANALYSIS IN CLINICAL-TRIALS [J].
DERSIMONIAN, R ;
LAIRD, N .
CONTROLLED CLINICAL TRIALS, 1986, 7 (03) :177-188
[10]   Health and disability costs of depressive illness in a major US corporation [J].
Druss, BG ;
Rosenheck, RA ;
Sledge, WH .
AMERICAN JOURNAL OF PSYCHIATRY, 2000, 157 (08) :1274-1278